Breaking Finance News

UroGen Pharma (NASDAQ:URGN) target price raised to $51.00, reported today by Oppenheimer

UroGen Pharma (NASDAQ:URGN) had its price target upped to $51.00 by Oppenheimer in an issued report released 11/15/2017. The new target price indicates a possible upside of 0.61% based on the company's previous closing price.

Previously on Tuesday May 30, 2017, Oppenheimer Holdings Inc. reported about UroGen Pharma (NASDAQ:URGN) raised the target price from $0.00 to $32.00. At the time, this indicated a possible upside of 0.73%.

Yesterday UroGen Pharma (NASDAQ:URGN) traded 0.22% higher at $31.73. The company’s 50-day moving average is $17.12 and its 200-day moving average is $17.12. The last stock close price is up 8.20% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 16,775 shares of the stock were exchanged, down from an average trading volume of 146,206

See Chart Below

UroGen Pharma (NASDAQ:URGN)

UroGen Pharma has a 52 week low of $13.01 and a 52 week high of $20.02 UroGen Pharma’s market capitalization is presently $0.

General Company Details For UroGen Pharma (NASDAQ:URGN)

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.